LivaNova’s (LIVN) Buy Rating Reiterated at Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research note issued on Wednesday, Benzinga reports. They presently have a $72.00 price target on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 15.70% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird upped their target price on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, February 22nd. Barclays increased their price objective on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Mizuho reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Wednesday, March 27th. Finally, StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $64.40.

LivaNova Stock Performance

LIVN traded up $6.48 during midday trading on Wednesday, hitting $62.23. 1,604,836 shares of the company traded hands, compared to its average volume of 628,205. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $3.37 billion, a PE ratio of 192.91 and a beta of 0.89. The company’s 50-day moving average is $54.32 and its 200 day moving average is $50.77. LivaNova has a 52 week low of $42.75 and a 52 week high of $62.38.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.81 EPS. On average, research analysts expect that LivaNova will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LIVN. Headlands Technologies LLC purchased a new stake in LivaNova in the third quarter worth about $72,000. Picton Mahoney Asset Management acquired a new position in LivaNova in the 3rd quarter worth approximately $91,000. Vanguard Personalized Indexing Management LLC acquired a new position in LivaNova in the 3rd quarter worth approximately $217,000. AlphaMark Advisors LLC acquired a new position in LivaNova in the 3rd quarter worth approximately $244,000. Finally, Jump Financial LLC acquired a new position in LivaNova in the 3rd quarter worth approximately $273,000. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.